Ravio raises $12m Series A to modernise compensation data for global workforces
8.5.2025 09:00:00 CEST | Business Wire | Press Release
Ravio has raised a $12m Series A funding round led by Spark Capital (US) with participation from Blackbird (Australia) and Cherry Ventures (Europe) to modernise how companies manage compensation with real-time market data and decision making tools.
Ravio counts leading consumer brands like Just Eat Takeaway and Octopus Energy among its customers, alongside fintech leaders such as Wise, Adyen, and Mollie. Popular tech names like Zoopla and Skyscanner have also chosen Ravio to set their compensation strategies.
The compensation data gap
Despite representing 70% of operating costs, most companies make these important decisions using patchy data that's 12-18 months old. This outdated approach creates significant issues:
- Talent leaves when underpaid compared to current market rates
- Companies overspend on some roles while struggling to attract talent in others
- Pay inequities develop as new hires and existing staff operate from different reference points
"The idea for Ravio was born from running compensation reviews during the early days of building Deliveroo," said Vaso Parisinou, Chief People Officer at Ravio. "We were scaling rapidly, and it was painful finding data from relevant companies. I was building bands across countries, ensuring my data reflected the current market, and trying to fill in gaps for remote markets. It was impossible.”
Breaking through compensation complexity
"Market data hasn't kept pace with today's dynamic market," said Merten Wulfert, co-founder and CEO of Ravio. "We're bringing decades-old survey methodology into the modern age by plugging directly into our customers' HR systems. This approach automates the data collection process and lets us continuously analyse market movements as they happen."
Companies that have switched to Ravio's real-time compensation data platform are seeing immediate benefits. HERO Software, a German SaaS company growing from 100 to 250 employees this year, used Ravio to transform their compensation strategy.
"When we built salary bands using Ravio, we could immediately see a few outliers – it was easy to spot pay equity issues," explains Anna-Lena Grimm, Director of People & Culture at HERO.
The end of aged data
Ravio's platform delivers relevant market data across 46+ countries and 100+ roles, helping companies make informed decisions quickly. The platform provides:
- Continuously updated live total rewards benchmarks
- An easy way to benchmark entire organisations against current data
- Tools built specifically to help modern compensation leaders simplify pay bands infrastructure, run merit cycles, and prevent pay inequalities
Customers securely connect data from their HR software via API, which is then anonymously aggregated into market-level benchmarks, with a give-to-get model. They can then compare their salary, equity and benefits packages to today’s market – with filters for headcount, funding stage, and industry. Then, whenever employees join, leave, or receive pay changes, the update syncs back to Ravio.
"Access to Ravio's live market data means no more headaches from delayed data sets or having to age compensation data," explains Jodi Slomp, VP People at Mollie. "Ravio offers real-time data with amazing visualisations."
"What I love about Ravio is the ability to track what's going on in today's market," said Evert Kraav, Senior Compensation Manager at Bolt. "Now, we can benchmark against current market rates in real-time."
Accelerating Ravio's global expansion
With Series A funding, Ravio will continue its international expansion to help compensation Rewards leaders access modern tooling needed to deploy competitive pay strategies.
"After supporting 1,200+ companies, we've seen how compensation leaders are put in tough positions with insufficient data and outdated tooling," said Raymond Siems, Chief Product & Technology Officer at Ravio. "We've built what our customers told us they need: real-time insights and decision-making tools without painful or time-consuming admin. Our mission is to empower compensation teams to lead with accurate, defensible data in every conversation."
Ravio plans to use the new funding to:
- Continue growing a comprehensive dataset with expanded regions and industry coverage
- Develop advanced market insights, including new hire benchmarks and predictive analytics
- Invest in best-in-class tools for efficient compensation management
"We're excited to double down on our previous investment in Ravio by leading their Series A," said Alex Finkelstein at Spark Capital. "Getting compensation right is challenging for companies of any size and industry. We believe Ravio is positioned to become the industry standard for real-time compensation data."
About Ravio
Founded in 2022, Ravio provides the data and tools companies need to achieve compensation confidence. By delivering real-time market insights and modern compensation management software, Ravio helps forward-thinking businesses avoid the "compensation debt" that occurs when pay practices fall out of alignment with market realities.
Following its Series A funding round, Ravio is giving free benchmarking access for 2 months to companies with more than 100 employees. Get a 60-day free trial at ravio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250508884441/en/
Contacts
Media Contact:
Name: Roy Blanga
Title: Founder and co-CEO
Organization: Ravio
Email: roy@ravio.com
LinkedIn: https://www.linkedin.com/in/roy-blanga-a830261/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.c
om%2Fin%2Froy-blanga-a830261%2F&esheet=54251143&newsitemid=20250508884441&lan=en
-US&anchor=https%3A%2F%2Fwww.linkedin.com%2Fin%2Froy-blanga-a830261%2F&index=2&m
d5=640d793601241ef3246819980fc85b3f
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom